Researcher

Shengli Xu joined the Institute of Molecular and Cell Biology (IMCB), Singapore, beginning his PhD studies in 1998. Upon obtaining his PhD in Immunology in 2003, Xu pursued postdoctoral research, first as a Research Fellow at IMCB, and later as a Senior Research Fellow at Singapore Immunology Network (SIgN) until 2009. In 2009, he joined Bioprocessing Technology Institute (BTI) as a Research Scientist and progressed to become a Senior Lead Research Scientist and a Group Leader. In 2020, Xu rejoined SIgN as a Principal investigator to lead the B Cell Immunology Group. He is also an adjunction assistant professor at the Department of Physiology, NUS. Xu’s research primarily focuses on B-cell immunology and the development of antibody-based immunotherapy.